RLMD vs SGMO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RLMD Captures Institutional Edge (3โ1 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Relmada Therapeutics, Inc. Common Stock (RLMD) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while SGMO counters with relative strength in Valuation. Fundamentally, RLMD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SGMO at 0.4x Forward P/E and -175.5% operating margin (+88.4% YoY). In options structure, RLMD sits in BREAKDOWN (36th %ile IV; Dealer Gamma Walls on Pro) against SGMO sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Revenue & Operating Margin Trajectory (USD)
| Period | RLMD Revenue | SGMO Revenue | RLMD Op. Margin | SGMO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2012 | $0M | N/A | -151.8% | N/A | RLMD |
| FY2013 | $0M | N/A | -877.7% | N/A | RLMD |
| Q1 '25 | N/A | $30M | N/A | -460.3% | SGMO |
| Q1 '26 | N/A | $10M | N/A | -2215.4% | SGMO |
| Q2 '25 | N/A | $70M | N/A | -97.5% | SGMO |
| Q3 '25 | N/A | $0M | N/A | -6119.3% | SGMO |
| Q4 '25 | N/A | $60M | N/A | -175.5% | SGMO |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RLMD | SGMO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $421.3M | $55.9M | Larger Scale | RLMD |
| Trailing P/E Ratio Valuation | N/M | 0.4x | Lower Multiple | SGMO |
| Forward P/E Ratio Valuation | N/M | 0.4x | Lower Multiple | SGMO |
| Revenue Growth (YoY) Growth | +0.0% | +88.4% | Higher Growth | SGMO |
| Operating Margin (TTM) Profitability | 0.0% | -175.5% | Higher Margin | RLMD |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -64.7% | -2891.8% | Higher ROE | RLMD |
| 52-Week Range Position Momentum | 11% ($3โ$8) | 9% ($0โ$1) | Stronger Trend | RLMD |
| Beta / 30D Volatility Risk Regime | 1.58ฮฒ ยท 93% Vol | 1.49ฮฒ ยท 206% Vol | Lower Realized Risk | RLMD |
| Unified Institutional Score Composite Signal | 35.3 / 100 (SELL) | 52.0 / 100 (HOLD) | Higher Composite | SGMO |